The articles listed on this page are from a variety of sources. 
1. The staff of DBS-STN often attends conferences or educational opportunities both nationally and internationally, and a brief understandable write-up of the information presented at the event will be provided for our readers to review. 
2. DBS-STN staff also identifies or writes various articles related to topics that are thought to be of interest for the reader of www.DBS-STN.org. 

Browse by Topic:
Search:

Titan Pharmaceuticals Receives Feedback from FDA on Ropinirole Implant Development Program for PD


(March 7, 2016) - Titan Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration has provided written feedback on the initial development plan for its proprietary ropinirole hydrochloride (HCL) implant for Parkinson's disease. The ropinirole implant is designed for the long-term, continuous delivery of ropinirole HCL for the treatment of signs and symptoms of Parkinson's disease. Read more…



Article Archive

back